How much revenue does Changchun High-Tech Industry (Group) make?

Changchun High-Tech Industry (Group) reported 13.47 billion CNY in revenue for fiscal year 2024, down 7.6% from 14.57 billion CNY in fiscal year 2023. In Q2 2025 revenue was 3.61 billion CNY.

What is Changchun High-Tech Industry (Group)'s largest business segment?

Pharmaceutical Industry, with 11.17 billion CNY or 92% of segment revenue in fiscal year 2025. Next: Real Estate (7%) and Service Industry (1%).

Where does Changchun High-Tech Industry (Group) make most of its revenue?

China: 99% of revenue by region in fiscal year 2025, followed by Foreign (1%).

What companies are similar to Changchun High-Tech Industry (Group)?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ), Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS), Humanwell Healthcare (Group) Co.,Ltd. (600079.SS), Livzon Pharmaceutical Group Inc. (000513.SZ).

Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) Stock

About Changchun High-Tech Industry (Group) Co., Ltd.

Changchun High-Tech Industry (Group) Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells biopharmaceuticals and traditional Chinese medicines products in China. The company offers recombinant human growth hormone injection; recombinant human follicle stimulating hormone for injection; herpes zoster vaccines; live attenuated varicella vaccine; freeze-dried nasal...

At a glance

Changchun High-Tech Industry (Group) reported revenue of 13.47 billion CNY for fiscal year 2024, down 7.6% from fiscal year 2023, and net income of 2.58 billion CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 3.61 billion CNY, up 4.2% from a year before. Its largest business segment, Pharmaceutical Industry, brought in 92% of segment revenue in fiscal year 2025; China was the largest region with 99%.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.